LVM Capital Management Ltd. MI Sells 554 Shares of Stryker Co. (NYSE:SYK)

LVM Capital Management Ltd. MI trimmed its position in Stryker Co. (NYSE:SYK) by 1.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,260 shares of the medical technology company’s stock after selling 554 shares during the quarter. Stryker accounts for 1.4% of LVM Capital Management Ltd. MI’s portfolio, making the stock its 19th largest position. LVM Capital Management Ltd. MI’s holdings in Stryker were worth $13,416,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. ST Germain D J Co. Inc. grew its position in Stryker by 14.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 2,362 shares of the medical technology company’s stock valued at $850,000 after acquiring an additional 300 shares during the period. Rempart Asset Management Inc. boosted its stake in shares of Stryker by 5.0% in the 4th quarter. Rempart Asset Management Inc. now owns 49,496 shares of the medical technology company’s stock valued at $17,821,000 after purchasing an additional 2,351 shares in the last quarter. Bath Savings Trust Co grew its holdings in shares of Stryker by 0.7% in the 4th quarter. Bath Savings Trust Co now owns 113,412 shares of the medical technology company’s stock worth $40,834,000 after purchasing an additional 823 shares during the last quarter. Regent Peak Wealth Advisors LLC acquired a new stake in shares of Stryker during the 4th quarter worth about $204,000. Finally, CWA Asset Management Group LLC lifted its holdings in Stryker by 3.5% during the 4th quarter. CWA Asset Management Group LLC now owns 3,854 shares of the medical technology company’s stock valued at $1,388,000 after purchasing an additional 131 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. UBS Group raised their price objective on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Piper Sandler reaffirmed an “overweight” rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a report on Wednesday, October 30th. BTIG Research boosted their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. lifted their price target on Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $405.80.

Stryker Stock Up 0.6 %

Shares of NYSE SYK traded up $2.32 during midday trading on Friday, reaching $366.42. The company’s stock had a trading volume of 607,542 shares, compared to its average volume of 1,157,611. The stock has a 50 day simple moving average of $375.42 and a 200-day simple moving average of $357.51. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $139.69 billion, a price-to-earnings ratio of 39.27, a PEG ratio of 2.82 and a beta of 0.95. Stryker Co. has a fifty-two week low of $306.10 and a fifty-two week high of $398.20.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same quarter in the prior year, the business posted $2.46 EPS. The business’s revenue was up 11.9% compared to the same quarter last year. Equities research analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. This is an increase from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. The ex-dividend date is Tuesday, December 31st. Stryker’s payout ratio is currently 36.01%.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.50% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.